EODData

FRA, CUP: Chugai Pharmaceutical Co. Ltd

23 Jan 2026
LAST:

46.27

CHANGE:
 1.19
OPEN:
46.37
HIGH:
46.37
ASK:
0.00
VOLUME:
25
CHG(%):
2.64
PREV:
45.08
LOW:
46.27
BID:
0.00
 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
23 Jan 2646.3746.3746.2746.2725
22 Jan 2644.9545.0844.9545.0825
21 Jan 2644.2844.3344.2644.2625
20 Jan 2644.0844.0843.7543.7525
19 Jan 2644.2244.4044.1844.1825
16 Jan 2644.6544.6844.2944.2925
15 Jan 2645.9746.0745.9446.0725
14 Jan 2645.6045.7245.6045.7225
13 Jan 2645.1446.0345.1146.0325
12 Jan 2646.2246.2246.1746.17345

PROFILE

Name:Chugai Pharmaceutical Co. Ltd
About:Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Perjeta, Polivy, Tecentriq, and Phesgo; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept for immunosuppressant; Edirol, an osteoporosis agent; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi for spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Ronapreve, an anti-SARS-CoV-2 monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody. The company has strategic alliances and collaboration with Roche Group; research collaboration and option to license agreement with Araris Biotech AG to develop ADCs using Araris AraLinQ technology; and research and license agreement with Gero PTE. LTD. to develop novel therapies for age-related diseases. The company was formerly known as Chugai Shinyaku Shokai and changed its name to Chugai Pharmaceutical Co., Ltd. in January 1943. Chugai Pharmaceutical Co., Ltd. was founded in 1925 and is headquartered in Chuo-ku, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.
Sector:Healthcare
Address:Nihonbashi Mitsui Tower, Chuo, Japan, 103-8324
Website:https://www.chugai-pharm.co.jp
ISIN:JP3519400000
LEI:529900T9LAII161DCN95

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

FUNDAMENTALS

Trailing P/E:34.28 
Forward P/E:0.31 
PEG Ratio:1.35 
Price to Sales:0.06 
Price to Book:7.14 
Profit Margin:0.33 
Operating Margin:0.47 
Return on Assets:0.16 
Return on Equity:0.22 
DivYield:0.02 
Div/Share:107.00 
Revenue:6.585B 
EBITDA:2.941B 
Shares:1.646B 
Market Cap:76.147B 

TECHNICAL INDICATORS

MA5:44.713.5%
MA10:45.182.4%
MA20:45.032.8%
MA50:45.002.8%
MA100:42.0010.2%
MA200:42.498.9%
STO9:96.18 
STO14:96.18 
RSI14:54.61
MTM14:1.38
ROC14:0.03 
ATR:0.72 
Week High:46.370.2%
Week Low:43.755.8%
Month High:46.370.2%
Month Low:43.758.9%
Year High:52.8514.2%
Year Low:32.8840.7%
Volatility:12.46 

RECENT SPLITS

Date Ratio
29 Jun 20203-1

RECENT DIVIDENDS

Date Amount
27 Jun 2025$0.71
27 Dec 2024$0.32
27 Jun 2024$0.23
28 Dec 2023$0.23
29 Jun 2023$0.23
29 Dec 2022$0.23
29 Jun 2022$0.22
29 Dec 2021$0.26
29 Jun 2021$0.17
29 Dec 2020$0.14